

CRAIG MARTIN CREWS, Ph.D.

Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology
Department of Chemistry
Department of Pharmacology
Yale University

EDUCATION

1987-1993 **Ph.D.**, Biochemistry, Harvard, with Dr. R. Erikson (*thesis project: Purification/cloning of MEK1*)
1986-1987 **DAAD Fellow**, Universität Tübingen, Germany
1982-1986 **B.A., Chemistry**, (minor in Biology), University of Virginia

PROFESSIONAL EXPERIENCE

2015 **Director**, Program for Innovative Therapeutics for Connecticut's Health ([PITCH](#))
2013 **Founder**, [Arvinas](#), LLC (oncology-focused biotech)
2010-2003 **Lewis B. Cullman Professor** of Molecular, Cellular, and Developmental Biology
2003 **Co-Founder**, [Proteolix](#), Inc. (*sold to Onyx Pharmaceuticals, 2009*)
2003-2003 **Executive Director**, [Yale Center for Molecular Discovery](#)
2003-2003 **PI**, NIH T32 Chemistry and Biology Interface (CBI) Training Grant (T32GM067543)
2001-2007 **Assoc. Prof.** → **Professor**, Yale, Dept of Chemistry
1998-2007 **Asst. Prof.** → **Professor**, Yale School of Medicine, Dept of Pharmacology
1995-2007 **Asst. Prof.** → **Professor**, Yale, Dept of Molecular, Cellular & Dev. Biology (*tenured 2001*)
1993-1995 **Postdoctoral Fellow**, Dept. of Chemistry, Harvard University, with Dr. Stuart Schreiber

HONORS AND AWARDS

2018 **Pierre Fabre Award** for Therapeutic Innovation
2018 **Khorana Prize**, Royal Society of Chemistry
2017 **AACR Award for Outstanding Achievement in Chemistry in Cancer Research**
2015 **Translational Research Prize**, Yale Cancer Center
2015 **NIH R35 Outstanding Investigator Award** (National Cancer Institute)
2014 **UCB-Ehrlich Award for Excellence in Medicinal Chemistry** (Eur. Fed. of Med. Chemistry)
2013 **Entrepreneur of the Year**, Connecticut United for Research Excellence (CURE)
2013 **Fellow**, American Association for the Advancement of Science (AAAS)
2011 **Senior Scholar Award**, Ellison Medical Foundation
2010-2013 **Visiting Professor (Gast Professor)**, Universität Konstanz, Germany
2010 **Lewis B. Cullman Professor** of Molecular, Cellular, and Developmental Biology
2006 **Bessel Research Award**, Alexander von Humboldt Foundation, Germany
2005-1999 **Fellow of the Royal Society of Chemistry**
1999 **Arthur Greer Memorial Prize** (Outstanding Junior Faculty in the Social or Natural Sciences)
1996-1998 **CaPCURE Research Award** (Association for the Cure of Cancer of the Prostate)
1996-1999 **Burroughs Wellcome Fund New Investigator Award**
1993-1995 **Cancer Research Institute Postdoctoral Fellowship**
1986-1987 **DAAD Research Fellowship** (German Academic Exchange Service)

EDITORIAL BOARDS

Cell Chemical Biology, ACS Chemical Biology, ChemBioChem, Molecular Biosystems, Chemistry & Biology, Molecular and Cellular Proteomics

PATENTS

'Enzyme Inhibition' Patent US 6,831,099 B1
'Enzyme Inhibition' Patent US 7,476,650
'Proteolysis-Targeting Chimeric Pharmaceutical' Patent US 7,041,298
'Proteolysis-Targeting Chimeric Pharmaceutical' Patent US 7,208,157
'Compounds for Enzyme Inhibition' Patent US 7,232,818
'Compounds for Enzyme Inhibition' Patent US 7,491,704
'Compounds for Enzyme Inhibition' Patent US 8,088,741
'Compounds for Enzyme Inhibition' Patent US 8,129,346

FDA APPROVED DRUGS

Carfilzomib/Kyprolis™ (based on the YU101 structure): approved for relapsed multiple myeloma (7/20/12)

LABORATORY WEBSITE:

crewslab.yale.edu